이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Morphic Holding 관리

관리 기준 확인 3/4

Morphic Holding's CEO는 Praveen Tipirneni, Jul2015 에 임명되었습니다 의 임기는 8.92 년입니다. 총 연간 보상은 $ 8.91M, 6.9% 로 구성됩니다. 6.9% 급여 및 93.1% 보너스(회사 주식 및 옵션 포함). 는 $ 17.19M 가치에 해당하는 회사 주식의 1.31% 직접 소유합니다. 17.19M. 경영진과 이사회의 평균 재임 기간은 각각 3.2 년과 7 년입니다.

주요 정보

Praveen Tipirneni

최고 경영자

US$8.9m

총 보상

CEO 급여 비율	6.9%
CEO 임기	8.9yrs
CEO 소유권	1.3%
경영진 평균 재임 기간	3.2yrs
이사회 평균 재임 기간	7yrs

최근 관리 업데이트

Recent updates

We're Hopeful That Morphic Holding (NASDAQ:MORF) Will Use Its Cash Wisely

Jan 20

Companies Like Morphic Holding (NASDAQ:MORF) Are In A Position To Invest In Growth

Sep 29

We're Interested To See How Morphic Holding (NASDAQ:MORF) Uses Its Cash Hoard To Grow

Jun 07

What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates

Feb 15

We're Hopeful That Morphic Holding (NASDAQ:MORF) Will Use Its Cash Wisely

Jan 03

What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates

Nov 08

Morphic GAAP EPS of -$0.68 beats by $0.17, revenue of $60.2M

Aug 03

Revenue Downgrade: Here's What Analysts Forecast For Morphic Holding, Inc. (NASDAQ:MORF)

May 06

Analyst Forecasts Just Became More Bearish On Morphic Holding, Inc. (NASDAQ:MORF)

Mar 01

Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation

Feb 17

Independent Director Vikas Goyal Just Bought A Handful Of Shares In Morphic Holding, Inc. (NASDAQ:MORF)

Mar 09

Did Business Growth Power Morphic Holding's (NASDAQ:MORF) Share Price Gain of 126%?

Feb 24

How Many Morphic Holding, Inc. (NASDAQ:MORF) Shares Have Insiders Sold, In The Last Year?

Jan 20

Morphic Holding (MORF) Presents At 39th Annual Healthcare Conference - Slideshow

Jan 14

Companies Like Morphic Holding (NASDAQ:MORF) Can Afford To Invest In Growth

Dec 16

CEO 보상 분석

Praveen Tipirneni 의 보수는 Morphic Holding 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$161m
Dec 31 2023	US$9m	US$614k	-US$152m
Sep 30 2023	n/a	n/a	-US$136m
Jun 30 2023	n/a	n/a	-US$130m
Mar 31 2023	n/a	n/a	-US$64m
Dec 31 2022	US$11m	US$602k	-US$59m
Sep 30 2022	n/a	n/a	-US$56m
Jun 30 2022	n/a	n/a	-US$51m
Mar 31 2022	n/a	n/a	-US$106m
Dec 31 2021	US$5m	US$579k	-US$96m
Sep 30 2021	n/a	n/a	-US$92m
Jun 30 2021	n/a	n/a	-US$61m
Mar 31 2021	n/a	n/a	-US$50m
Dec 31 2020	US$4m	US$559k	-US$45m
Sep 30 2020	n/a	n/a	-US$47m
Jun 30 2020	n/a	n/a	-US$61m
Mar 31 2020	n/a	n/a	-US$55m
Dec 31 2019	US$788k	US$498k	-US$43m
Sep 30 2019	n/a	n/a	-US$29m
Jun 30 2019	n/a	n/a	-US$27m
Mar 31 2019	n/a	n/a	-US$24m
Dec 31 2018	US$2m	US$402k	-US$24m

보상 대 시장: Praveen 의 총 보상 ($USD 8.91M )은 US 시장( $USD 5.67M ).

보상과 수익: Praveen 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Praveen Tipirneni (56 yo)

8.9yrs

테뉴어

US$8,907,684

보상

Dr. Praveen P. Tipirneni, M.D., has been a Director at Tectonic Therapeutic, Inc. He serves as an Independent Director at Panacea Acquisition Corp. II since April 6, 2021. He serves as Chief Executive Offi...

리더십 팀

이름	위치	테뉴어	보상	소유권
Praveen Tipirneni	CEO, MD & Director	8.9yrs	US$8.91m	1.31% $ 18.1m
Bruce Rogers	President	2.1yrs	US$4.88m	0.30% $ 4.1m
Timothy Springer	Founder	9.8yrs	US$539.99k	15.24% $ 209.9m
Marc Schegerin	CFO & COO	4.2yrs	US$4.65m	0.076% $ 1.0m
Robert Farrell	Senior VP of Finance & Chief Accounting Officer	4.4yrs	US$4.03m	0.070% $ 969.8k
Blaise Lippa	Chief Scientific Officer	2.1yrs	데이터 없음	데이터 없음
William DeVaul	General Counsel & Secretary	5.3yrs	US$2.24m	0.046% $ 633.3k
Aaron Pelta	Senior Vice President of Business & Corporate Development	2.2yrs	데이터 없음	데이터 없음
Joanne Gibbons	Senior Vice President of Regulatory Affairs	2.1yrs	데이터 없음	데이터 없음
Simon Cooper	Chief Medical Officer	less than a year	데이터 없음	데이터 없음

3.2yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: MORF 의 관리팀은 경험 ( 3.2 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Praveen Tipirneni	CEO, MD & Director	8.9yrs	US$8.91m	1.31% $ 18.1m
Timothy Springer	Founder	9yrs	US$539.99k	15.24% $ 209.9m
Norbert Bischofberger	Independent Director	5yrs	US$545.74k	0% $ 0
Joseph Slattery	Independent Director	5.1yrs	US$560.74k	0.018% $ 249.3k
Martin Edwards	Independent Director	3.5yrs	US$547.49k	0.0047% $ 65.3k
Gustav Christensen	Independent Chairman	8.4yrs	US$586.49k	0.20% $ 2.8m
Amir Nashat	Independent Director	7yrs	US$544.99k	0.00029% $ 4.0k
Scott L. Friedman	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Ulrich von Andrian-Werburg	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Shelia Violette	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Albert Robichaud	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Yury Popov	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음

7.0yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 이사회: MORF 의 이사회는 경험(평균 재직 기간 7 년)으로 간주됩니다.

Morphic Holding 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Morphic Holding, Inc., Annual General Meeting, Jun 04, 2024

Morphic Therapeutic Appoints Simon Cooper as Chief Medical Officer

Key Executive exercised options and sold US$174k worth of stock

Insufficient new directors

Morphic Holding, Inc. Announces Chief Executive Officer Changes

Morphic Holdings Inc. Announces Chief Executive Officer, Praveen Tipirneni Suffered an Emergent Medical Event and Taking Medical Leave of Absence

Recent updates

Morphic Holding, Inc., Annual General Meeting, Jun 04, 2024

Morphic Therapeutic Appoints Simon Cooper as Chief Medical Officer

Consensus revenue estimates decrease by 88%, EPS upgraded

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

We're Hopeful That Morphic Holding (NASDAQ:MORF) Will Use Its Cash Wisely

Key Executive exercised options and sold US$174k worth of stock

Insufficient new directors

Price target decreased by 10% to US$55.13

Consensus EPS estimates upgraded to US$3.41 loss

Morphic Holding, Inc. Announces Chief Executive Officer Changes

Third quarter 2023 earnings released: US$0.73 loss per share (vs US$0.78 loss in 3Q 2022)

Companies Like Morphic Holding (NASDAQ:MORF) Are In A Position To Invest In Growth

Price target decreased by 13% to US$65.38

Morphic Holdings Inc. Announces Chief Executive Officer, Praveen Tipirneni Suffered an Emergent Medical Event and Taking Medical Leave of Absence

CFO & COO notifies of intention to sell stock

Second quarter 2023 earnings released: US$0.92 loss per share (vs US$0.70 profit in 2Q 2022)

CEO, MD & Director exercised options and sold US$190k worth of stock

We're Interested To See How Morphic Holding (NASDAQ:MORF) Uses Its Cash Hoard To Grow

General Counsel & Secretary notifies of intention to sell stock

Price target increased by 14% to US$73.88

Price target increased by 14% to US$73.88

First quarter 2023 earnings: EPS and revenues miss analyst expectations

CFO & COO exercised options to buy US$279k worth of stock.

CFO & COO notifies of intention to sell stock

Consensus revenue estimates decrease by 29%, EPS upgraded

Full year 2022 earnings: EPS and revenues exceed analyst expectations

President exercised options and sold US$358k worth of stock

What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates

Morphic Holding, Inc. announced that it expects to receive $29.999954 million in funding

CEO, MD & Director exercised options and sold US$123k worth of stock

We're Hopeful That Morphic Holding (NASDAQ:MORF) Will Use Its Cash Wisely

Morphic Therapeutic AnnouncesInitiation of EMERALD-2 Phase 2b Clinical Trial of MORF-057 in Patients with Moderate-to-Severe Ulcerative Colitis

What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Morphic Therapeutic Presents New Positive MORF-057 Phase 1 Data at American College of Gastroenterology Annual Meeting 2022

Morphic Therapeutic Presents New Positive MORF-057 Phase 1 Data at UEG Week 2022

Consensus revenue estimates increase by 437%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Morphic GAAP EPS of -$0.68 beats by $0.17, revenue of $60.2M

Price target decreased to US$66.43

Morphic Therapeutic Appoints Joanne Gibbons as Senior Vice President of Regulatory Affairs

Morphic Holding, Inc. Announces Management Appointments

Revenue Downgrade: Here's What Analysts Forecast For Morphic Holding, Inc. (NASDAQ:MORF)

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Morphic Holding, Inc., Annual General Meeting, Jun 08, 2022

Price target decreased to US$74.50

Morphic Therapeutic Announces Management Appointments

Chief Scientific Officer exercised options and sold US$367k worth of stock

Consensus revenue estimates fall by 38%

Analyst Forecasts Just Became More Bearish On Morphic Holding, Inc. (NASDAQ:MORF)

Price target decreased to US$75.80

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Morphic Holding, Inc. Announces Retirement of Dr. Nilesh Kumar from the Board and Resign as Member of the Board and the Audit and Nominating and Governance Committees

Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation

Price target decreased to US$83.80

General Counsel & Secretary exercised options to buy US$827k worth of stock.

Price target decreased to US$95.00

Third quarter 2021 earnings released: US$0.69 loss per share (vs US$0.17 profit in 3Q 2020)

CFO & COO exercised options and sold US$246k worth of stock

We're Not Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn

CFO & COO exercised options and sold US$1.3m worth of stock

Morphic: Pioneering Integrin Medicines

Chief Scientific Officer notifies of intention to sell stock

Founder recently bought US$4.2m worth of stock

Consensus EPS estimates fall to -US$2.73

Second quarter 2021 earnings released: US$0.77 loss per share (vs US$0.52 loss in 2Q 2020)

Morphic Holding (NASDAQ:MORF) Is In A Strong Position To Grow Its Business

Morphic Holding, Inc.(NasdaqGM:MORF) dropped from Russell 3000E Index

Insider notifies of intention to sell stock